http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2334579-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c01f70afd053f8f4b4221ce2ef40a41c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbcb74aff94405866f23711e4c48bd92 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2510-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 1998-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39d2f7c3647759dd9e03cc1f5fc63914 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68fdefa2147d6981115aec398eeb289b |
| publicationDate | 1999-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2334579-A |
| titleOfInvention | Sensitivity of cancer cells to anti-cancer agents involving measurement of properties of signal transduction factors |
| abstract | A method for the measurement of the sensitivity of a cancer cell to an anti-cancer agent comprises assay of a sample for the mutational status, expression and/or function of a negative signal transduction factor (NSTF), and the mutational status, expression and/or function of a positive signal transduction factor (PSTF), provided that assay of the radiosensitivity of wild-type p53 cancer cells for Raf-1 protein is effected using an antibody thereto. The NSTF may be a factor which inhibits or arrests the cell cycle, causes cells to withdraw from the cell cycle, and/or causes apoptosis or other cell death thereby inhibiting cell division (especially a suppressor), or may be p53, p21 or a PSTF inhibitor (preferably a Raf-1 inhibitor, a cyclin D1 inhibitor or a cyclin-dependent kinase inhibitor). The PSTF may be a factor which stimulates cells to enter the cell cycle, initiates and/or effects DNA synthesis, and/or controls the passage of cells through the cell cycle, preferably an oncogene, a proto-oncogene, a gene which inhibits and/or controls cell cycle division, or a cell surface receptor (especially Raf-1 protein, cyclin D1 protein, or a cyclin-dependent kinase, particularly CDK1 or CDK4). The anti-cancer agent may be ionising radiation, a molecular anti-cancer agent (preferably a chemotherapeutic agent) or a biological cancer therapy agent. Kits, for performing the methods, are described. |
| priorityDate | 1998-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 197.